Spots Global Cancer Trial Database for Determination of Blood Tumor Cells

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Determination of Blood Tumor Cells

Official Title: Determination of Blood Tumor Cells Using Magnetic Nanoparticles

Study ID: NCT04290923

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Abnormalities Cell Epithelial

Interventions

Study Description

Brief Summary: Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .

Detailed Description: Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (EpCAM as marker)can be removed out of the blood with the help of these particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked to test their blood. Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid tumors in the blood such as lymphoma or leukemia (CD52 as marker).